Podcasts

PsA Podcast: Impact of Biological Sex on Advanced Therapies & Upadacitinib-related Malignancies

Join Philip Mease, Professor at the University of Washington School of Medicine and Director of Rheumatology Research at the Swedish Medical Centre in Seattle, USA, and Laura Coates, an Associate Professor, NIHR clinician scientist and senior clinical research fellow at the Oxford Psoriatic Arthritis Centre, as they discuss two important topics from the world of contemporary PsA treatment.

The first of the publications they will be reviewing sought to compare patient characteristics and efficacy and safety of advanced therapies between male and female patients with PsA participating in RCTs. They then go on to discuss a second publication describing malignancies in patients with a variety of rheumatic conditions treated with upadacitinib or active comparators.

AxSpA Podcast: Bimekizumab in AxSpA & Secukinumab Patient Clustering

Join us for the latest axSpA podcast! This month Dr Sofia Ramiro, consultant rheumatologist and senior researcher at Leiden University Medical Centre and Zuyderland Medical Centre, is joined once again by experts with a wealth of clinical knowledge. Joining her is Hideto Kameda, Professor of Internal Medicine at Toho University as well as Atul Deodhar, Professor of Medicine and Medical Director of Rheumatology Clinics in the Division of Arthritis & Rheumatic Diseases at Oregon Health & Science University in Portland, USA. Also joining this insightful group is Xenofon Baraliakos, Professor of Internal Medicine and Rheumatology at the Ruhr-University in Bochum, and Medical Director of the rheumatology centre Rheumazentrum Ruhrgebiet in Herne, Germany.

In the first paper discussed, the authors compared the efficacy and safety of bimekizumab with biologic/targeted synthetic disease-modifying antirheumatic drugs in nr-axSpA and AS. Our second paper then goes on to identify distinct clinical clusters based on patient demographics and baseline clinical indicators from the clinical development programme of secukinumab in patients with a variety of rheumatological conditions.

AxSpA Podcast: Safety and Efficacy of Tofacitinib and Bimekizumab

Join Doctor Sofia Ramiro as she is joined by Professors Atul Deodhar and Xenofon Baraliakos to discuss the latest top clinical research in the world of axSpA. In the first paper discussed, the authors evaluated the efficacy and safety of tofacitinib in bDMARD-naïve and TNF-IR AS patients. The second paper presents the results of two parallel clinical trials that investigated the safety and efficacy of bimekizumab.

PsA Podcast: Gender differences in treating PsA & safety of guselkumab in treating PsO and PsA

Join Peter Nash, Professor at the School of Medicine, Griffith University, and Director of the Rheumatology Research Unit on the Sunshine Coast, Australia, Philip Mease, Professor at the University of Washington School of Medicine, and Director of Rheumatology Research at the Swedish Medical Centre in Seattle, USA, as well as Laura Coates, an Associate Professor, NIHR clinician scientist and senior clinical research fellow at the Oxford Psoriatic Arthritis Centre as they discuss two intriguing aspects of the contemporary PsA treatment landscape. The first of the publications relates to the effects of gender on disease characteristics, treatment impact and treatment persistence. The second publication explores the long-term safety profile of guselkumab in the treatment of PsO and PsA.

Discussing Rheumatology: November 2023

Join Professor Iain McInnes in this month's Podcast, where he discusses the latest information and data in rheumatology. In this episode, he discusses two papers that look at the incidence of disease. The first paper, the GBD 2021 Other Musculoskeletal Disorders Collaborators systematically analysed the global burden of musculoskeletal disorders, and used these data to predict prevalence up to 2050 and the second paper, Yvette Meissner and her colleagues used the German RABBIT registry to investigate the relationship between MACE risk and JAK inhibitors, TNF inhibitors, and DMARDs.

Bimekizumab in treating bDMARD-naïve PsA & upadacitinib in treating csDMARD and bDMARD IR PsA

Join Peter Nash, Professor at the School of Medicine, Griffith University, and Director of the Rheumatology Research Unit on the Sunshine Coast, Australia and Laura Coates, an Associate Professor, NIHR clinician scientist and senior clinical research fellow at the Oxford Psoriatic Arthritis Centre, discussing two intriguing aspects of the contemporary PsA treatment landscape. The first of the publications relates to the safety and efficacy of bimekizumab in bDMARD-naïve patients with PsA through 52 weeks and the second is a publication exploring the real-world safety and efficacy of upadacitinib in patients with PsA and an inadequate response to csDMARDs or bDMARDs.